Findings

What do systematic reviews say?

2 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 66.7%

Three infusions of natalizumab (300 mg) vs placebo

Failure to induce clinical response at end of study · Patients with active Crohn's disease

Three infusions of natalizumab (300 mg) showed no clear difference in failure to induce clinical response at 10 weeks compared with placebo (high certainty).

2 findings from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.85 [0.72, 1]
1 study · 905 participants
High
Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.76 [0.67, 0.86]
2 studies · 1414 participants
High

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical response at end of study · Participants with active Crohn's disease despite current treatment with infliximab

The review found no eligible studies for this question.

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found